Zhitong Finance App News, Sinopharm Holdings (01099.HK) issued an announcement. On August 19, 2026, the company, Sinopharm Group and Sinopharm Co., Ltd. jointly entered into an equity transfer agreement with Sinopharm Hyundai. According to this, (i) the Company agreed to sell 30.13% of the company's target company Sinopharm Group Guorui Pharmaceutical Co., Ltd. (Guorui Pharmaceutical) at a cost of RMB 240 million; (ii) Sinopharm shares (a subsidiary of the Company) agreed to sell 12.06% of its target company shares to Sinopharm Hyundai for RMB 12.06% of its target company shares RMB 96.093 million; and (iii) Sinopharm Group agreed to sell 8.81% of its target company shares to Sinopharm Hyundai at a cost of RMB 70,1973 million. The total cost of the transfer of 51% of the above shares was RMB 406 million.

Zhitong Finance App News, Sinopharm Holdings (01099.HK) issued an announcement. On August 19, 2026, the company, Sinopharm Group and Sinopharm Co., Ltd. jointly entered into an equity transfer agreement with Sinopharm Hyundai. According to this, (i) the Company agreed to sell 30.13% of the company's target company Sinopharm Group Guorui Pharmaceutical Co., Ltd. (Guorui Pharmaceutical) at a cost of RMB 240 million; (ii) Sinopharm shares (a subsidiary of the Company) agreed to sell 12.06% of its target company shares to Sinopharm Hyundai for RMB 12.06% of its target company shares RMB 96.093 million; and (iii) Sinopharm Group agreed to sell 8.81% of its target company shares to Sinopharm Hyundai at a cost of RMB 70,1973 million. The total cost of the transfer of 51% of the above shares was RMB 406 million.